Can CEL-SCI’s Saudi Arabia deal turn Multikine into a real commercial oncology test?
Multikine still awaits a commercial breakthrough. CEL-SCI’s Saudi deal tests whether regional oncology access can change that trajectory.
What Oncolytics Biotech, Inc.’s latest data reveals about overcoming MSS colorectal resistance
Explore how Oncolytics Biotech, Inc.’s pelareorep data could reshape MSS colorectal cancer care. Discover durability insights and what comes next.
Could five-year survival data position KIMMTRAK as a durable standard in uveal melanoma care
Discover how Immunocore’s five-year KIMMTRAK data could reshape survival expectations in metastatic uveal melanoma. Read the full analysis.